|Acarbose Cardiovascular Evaluation|
The Acarbose Cardiovascular Evaluation (ACE) trial is a double-blind, randomised, multi-centre, cardiovascular intervention study coordinated by the University of Oxford Diabetes Trials Unit (DTU). It has been designed by Professors Rury Holman (Oxford University, UK), Hu Dayi (People's Hospital Peking University, China) and Pan Chang Yu (Chinese PLA General Hospital, Beijing, China).
ACE will be conducted in up to 150 hospitals in mainland China and Hong Kong commencing in 2008. The trial aims to determine whether reducing post prandial glycaemia with acarbose can reduce cardiovascular-related morbidity and mortality in patients with established cardiovascular disease (CVD) or acute coronary syndrome (ACS) who also have impaired glucose intolerance (IGT). Patients will be followed for a minimum of 4 years with the results expected in 2016.
You can apply to be a clinical centre using this form.
The ACE study is funded by Bayer HealthCare in an academic collaboration with the Diabetes Trials Unit.